PTSD rate at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of PTSD symptoms ‐ Clinician‐rated · adults (aged 18 and older) exposed to a traumatic event
1 finding from 1 review
Dropouts due to adverse events · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
PTSD rate at 3 months · adults (aged 18 and older) exposed to a traumatic event
It is very uncertain whether propranolol changes PTSD rate at 3 months compared with placebo (very low certainty).
1 finding from 1 review
Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Psychological well‐being and coping (primary outcome) · adults (aged 18 or older) with a diagnosis of stroke
1 finding from 1 review
Secondary outcome: quality of life · adults (aged 18 or older) with a diagnosis of stroke
1 finding from 1 review
Physical functional improvement (secondary outcome) · adults (aged 18 or older) with a diagnosis of stroke
1 finding from 1 review
Communication and cognitive functional improvement (secondary outcome) · adults (aged 18 or older) with a diagnosis of stroke
1 finding from 1 review
Physical activity · adults (aged 18 or older) with a diagnosis of stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: all adverse events · adults (aged 18 or older) with a diagnosis of stroke
1 finding from 1 review
All‐cause mortality · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes all‐cause mortality compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Cardiovascular events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes cardiovascular events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Total serious adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes total serious adverse events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes hospitalisation for heart failure compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes withdrawal due to adverse events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Length of hospital stay · patients age 10 years and older with periorbital or orbital cellulitis
It is very uncertain whether standard treatment plus systemic corticosteroids changes length of hospital stay compared with standard treatment alone (very low certainty).
1 finding from 1 review
Preservation of visual acuity · patients age 10 years and older with periorbital or orbital cellulitis
It is very uncertain whether standard treatment plus systemic corticosteroids changes preservation of visual acuity compared with standard treatment alone (very low certainty).
1 finding from 1 review